Efficacy and Safety of Standard of Care Plus Durvalumab in Patients with Limited Disease Small Cell Lung Cancer (DOLPHIN)
Phase 2
Recruiting
- Conditions
- Small Cell Lung Cancer Limited Stage
- Interventions
- Drug: standard of care
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Michael Hopp
- Target Recruit Count
- 105
- Registration Number
- NCT04602533
- Locations
- 🇩🇪
Klinik Löwenstein gGmbH, Löwenstein, Baden-Würtemberg, Germany
🇩🇪Klinikverbund Allgäu gGmbH, Immenstadt, Bayern, Germany
🇩🇪Asklepios Fachkliniken Muenchen Gauting, München Gauting, Bayern, Germany
AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
Phase 4
Active, not recruiting
- Conditions
- Non-squamous NSCLC
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Michael Hopp
- Target Recruit Count
- 34
- Registration Number
- NCT04413201
- Locations
- 🇩🇪
Sana-Klinikum Offenbach, Offenbach, Hessen, Germany
🇩🇪Klinikum Bremen-Ost, Bremen, Germany
🇩🇪Gemeinnützige Krankenhausbetriebsgesellschaft Konstanz Mbh, Konstanz, Germany
© Copyright 2025. All Rights Reserved by MedPath